Alpine Immune Sciences stock has undergone multiple analysts rating changes in the recent past.  Alpine Immune Sciences stock Target Raised by   Piper Sandler on 6/19/2020. In a note to investors, the firm issued a new target price of $21.00. The analysts previously had $8.00 target price. Piper Sandler’s price target would indicate a potential upside of 70.18% from the stock’s previous close.

Shares of Alpine Immune Sciences traded up $1.15 on Friday, reaching $12.10. 5733486 shares of the stock traded hands, compared to its average volume of 1368135. Shares of Alpine Immune Sciences started the day on up  at $12.10 on Friday. The firm’s 50 day moving average is $$3.72 and its 200 day moving average is $3.37.Alpine Immune Sciences  has a 12 month low of $11.00 and a 12 month high of $15.00. While on yearly highs and lows, Alpine Immune Sciences today has traded high as $13.75 and has touched $11.00 on the downward trend.

Alpine Immune Sciences Earnings and What to expect: 

Alpine Immune Sciences last announced its earnings data on May 14th, 2020. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.17. The business earned $1.09 million during the quarter, compared to analysts’ expectations of $0.38 million. Alpine Immune Sciences has generated ($2.28) earnings per share over the last year. Alpine Immune Sciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 11th, 2020 based off prior year’s report dates.

Earnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.38) to ($1.77) per share. The P/E ratio of Alpine Immune Sciences is -6.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Alpine Immune Sciences is -6.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Alpine Immune Sciences has a P/B Ratio of 7.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 76.10%
  • On 5/30/2019 VP James Paul Rickey Buy 10,000 at average share price of $4.95 which equates to $49,500.00 in money value.
  • On 2/8/2019 Major Shareholder Tiger Management L.L.C. Sell 25,000 at average price of  $5.85 with total value of : Not Data Available
  • On 1/18/2019 Director James N Topper Buy 372,439 at average price of  $5.37 with total value of : $1,999,997.43
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Alpine Immune Sciences

  • 6/19/2020 – Alpine Immune Sciences had its price target raised by analysts at Wedbush from $10.00 to $22.00. They now have an “outperform” rating on the stock.
  • 6/8/2020 – Alpine Immune Sciences had its “buy” rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock.
  • 5/26/2020 – Alpine Immune Sciences had its “outperform” rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
  • 5/26/2020 – Alpine Immune Sciences had its “buy” rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $17.00 price target on the stock.
  • See More Analyst Rating at: RATING

Other rating updates by Piper Sandler: 

  • 6/19/2020 – Umpqua is now covered by analysts at Piper Sandler. They set a “hold” rating and a $12.00 price target on the stock.
  • 6/19/2020 – Crispr Therapeutics had its “overweight” rating re-affirmed by analysts at Piper Sandler. They now have a $104.00 price target on the stock.
  • 6/19/2020 – Niu Technologies had its price target raised by analysts at Piper Sandler from $11.00 to $24.00. They now have an “overweight” rating on the stock.
  • 6/19/2020 – Electronic Arts was upgraded by analysts at Piper Sandler to an “overweight” rating. They now have a $133.00 price target on the stock, up previously from $126.00.
  • See More Analyst Rating at: RATING

Alpine Immune Sciences (NASDAQ:ALPN) Moving Average Technical Analysis

5 day Moving Average is $$7.19 And 5 day price change is $8.37 (224.40%)  with average volume for 5 day average is 9,186,540. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $4.65 and 20 day price change is $8.75 (260.66%) and average 20 day moving volume is 2,326,130. 50 day moving average is $3.72  and 50 day price change is $9.20 ( 317.24%)  and with average volume for 50 days is : 938,824. 200 day moving average is $3.37  and 200 day price change is $7.50 (163.04%)  and with average volume for 200 days is : 250,396.

See More Analyst Rating at: RATING



Source link